Title :

2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations

Author(s) :

Trzaska, Carole [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Amand, Séverine [Auteur]
Molécules de Communication et Adaptation des Micro-organismes [MCAM]
Bailly, Christine [Auteur]
Molécules de Communication et Adaptation des Micro-organismes [MCAM]
Leroy, Catherine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Marchand, Virginie [Auteur]
Duvernois-Berthet, Evelyne [Auteur]
Physiologie moléculaire et adaptation [PhyMA]
Saliou, Jean-Michel [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Benhabiles, Hana [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Werkmeister, Elisabeth [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Chassat, Thierry [Auteur]
Institut Pasteur de Lille
Guilbert, Romain [Auteur]
Institut Pasteur de Lille
Hannebique, David [Auteur]
Institut Pasteur de Lille
Mouray, Anthony [Auteur]
Institut Pasteur de Lille
Copin, Marie-Christine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Moreau, Pierre-Arthur [Auteur]
Adriaenssens, Eric [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Kulozik, Andreas [Auteur]
Westhof, Eric [Auteur]
Architecture et Réactivité de l'ARN [ARN]
Tulasne, David [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Motorin, Yuri [Auteur]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Rebuffat, Sylvie [Auteur]
Molécules de Communication et Adaptation des Micro-organismes [MCAM]
Lejeune, Fabrice [Auteur correspondant]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Journal title :

Nature Communications

Pages :

1509

Publisher :

Nature Publishing Group

Publication date :

2020-03-20

ISSN :

2041-1723

HAL domain(s) :

Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire/Biologie moléculaire
Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire/Génomique, Transcriptomique et Protéomique [q-bio.GN]

English abstract : [en]

Nonsense mutations cause about 10% of genetic disease cases, and no treatments are available. Nonsense mutations can be corrected by molecules with nonsense mutation readthrough activity. An extract of the mushroom Lepista ...
Show more >Nonsense mutations cause about 10% of genetic disease cases, and no treatments are available. Nonsense mutations can be corrected by molecules with nonsense mutation readthrough activity. An extract of the mushroom Lepista inversa has recently shown high-efficiency correction of UGA and UAA nonsense mutations. One active constituent of this extract is 2,6-diaminopurine (DAP). In Calu-6 cancer cells, in which TP53 gene has a UGA nonsense mutation, DAP treatment increases p53 level. It also decreases the growth of tumors arising from Calu-6 cells injected into immunodeficient nude mice. DAP acts by interfering with the activity of a tRNA-specific 2'-O-methyltransferase (FTSJ1) responsible for cytosine 34 modification in tRNATrp. Low-toxicity and high-efficiency UGA nonsense mutation correction make DAP a good candidate for the development of treatments for genetic diseases caused by nonsense mutations.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL